Business Context and Reporting Period
This Form 8-K Current Report was filed by Aadi Bioscience, Inc. (trading symbol: AADI) on March 17, 2022. The registrant is a Delaware corporation with principal executive offices in Pacific Palisades, California. The filing reports the entry into a material definitive agreement regarding a new equity financing program.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the authorization of an "at-the-market" (ATM) equity offering program with aggregate gross proceeds of up to $75,000,000. The company will pay a commission of 3.0% of gross sales proceeds to the sales agent, Cowen and Company, LLC.
Material Changes
The material change reported is the execution of a Sales Agreement with Cowen and Company, LLC. This agreement allows the company to sell shares of its common stock from time to time at its sole discretion. The offering is subject to the company's existing shelf registration statement on Form S-3 (File No. 333-255129), which became effective on April 15, 2021.
Outlook, Risks, and Management Commentary
- Management Discretion: The company retains full control over the sale parameters, including the number of shares, timing, daily sales limits, and minimum price thresholds.
- Flexibility: The company has no obligation to sell any shares and may suspend sales at any time.
- Termination: The agreement terminates upon the sale of all authorized shares or earlier termination in accordance with its terms.
- Risks: The filing notes that the sale of shares is subject to securities laws and that the report does not constitute an offer to sell in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current share price and trading volume on The Nasdaq Capital Market to assess potential dilution impact.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific minimum price floors or daily volume caps.
- Check subsequent filings to determine if and when the company has actually executed sales under this program.
- Confirm the company's current cash position and burn rate to understand the urgency of utilizing this $75 million facility.